Compare Enveric Biosciences Inc (ENVB) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while iShares 1 3 Year Treasury Bond ETF trades at $81.18 (market cap $26.68B). The key difference: iShares 1 3 Year Treasury Bond ETF is far larger — about 3923.5× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 4,077,691). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| ENVB | SHY | |
|---|---|---|
Market Cap | $6.80M | $26.68B |
Volume | 64,867 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $10.80 | $83.18 |
52-Week Low | $1.27 | $81.05 |
Typical Hold Time | 14 Days | 63 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
SHY, a US stock, trades at $81.16, up 0.04% on the day. Technical indicators are bearish, with moving averages signaling sell pressure and oscillators neutral. The stock faces resistance and support near $81. Recent corporate actions include dividend payments, with the latest at $0.24 per share. Financial ratios are unavailable in the provided data, limiting fundamental analysis.
The outlook for SHY is cautious due to bearish technical signals and a lack of current fundamental data. Investment opportunities may arise from dividend income, but risks include market volatility and reliance on broader economic conditions. Investors should seek updated financials for a complete assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
